Advice
Following a full submission
ziconotide (Prialt®) is not recommended for use within NHS Scotland for the treatment of severe, chronic pain in patients who require intrathecal analgesia. Ziconotide, compared to placebo, improved pain scores in patients with chronic severe intractable pain despite treatment with systemic and/or intrathecal analgesia.
However, the manufacturer did not present a sufficiently robust economic analysis to gain acceptance by SMC.
Download detailed advice54KB (PDF)
Medicine details
- Medicine name:
- ziconotide 100 micrograms/ml solution for infusion (Prialt)
- SMC ID:
- 405/07
- Indication:
- for the treatment of severe, chronic pain in patients who require intrathecal analgesia
- Pharmaceutical company
- Eisai Ltd
- BNF chapter
- Central nervous system
- Submission type
- Full
- Status
- Not recommended
- Date advice published
- 08 October 2007